Supporting information

IMPROVEMENT OF KEY MOLECULAR EVENTS LINKED TO ALZHEIMER'S DISEASE PATHOLOGY USING POSTBIOTICS

Gabriela Agustina Bulacios[1], Pablo Gabriel Cataldo[2], Johana Romina Naja[1], Elena Posse de Chaves[3], María Pía Taranto[2], Carlos Javier Minahk[4], Elvira María Hebert[2*] and María Lucila Saavedra[1*]

[1]Laboratorio de Genética y Biología Molecular, CERELA-CONICET, Centro de Referencia para Lactobacilos, Chacabuco 145, San Miguel de Tucumán (T4000ILC), Tucumán, Argentina.

[2]Laboratorio de Tecnología, CERELA-CONICET, Centro de Referencia para Lactobacilos, Chacabuco 145, San Miguel de Tucumán (T4000ILC), Tucumán, Argentina.

[3] Departments of Pharmacology and Medicine and the Centre for Neuroscience, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada

[4] Instituto Superior de Investigaciones Biológicas, Chacabuco 461. San Miguel de Tucumán, Argentina.



Fig. S1. IL1β expression in BV2 cells following co-incubation of oA$\beta_{1\text{-}42}$ (5μM) with increasing concentrations of ascorbic acid (AA) for 8 h.



Fig. S2. Dose- response curve of donepezil inhibition on acetylcholinesterase activity from human erythrocytes (AChE-E) prepared as described in Material and Methods section. The AChE inhibition (%) is plotted vs logarithmic concentration of donepezil (3 fM to 30μM). The results are expressed as mean ± standard deviation of three independent experiments. Data were fitted by a four-parametric logistic model.